Patents by Inventor Lindsey Shelton

Lindsey Shelton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11931373
    Abstract: Disclosed herein are compounds and methods for inhibiting Aha1 for the treatment of tauopathies and neurodegenerative diseases. The Aha1 inhibitor may reduce the interaction between Aha1 and Hsp90. The Aha1 inhibitor may reduce aggregation of tau protein. The Aha1 inhibitor may include a compound selected from KU-177, KU-174, and KU-308.
    Type: Grant
    Filed: April 15, 2022
    Date of Patent: March 19, 2024
    Assignees: University of South Florida, University of Kansas
    Inventors: Chad Dickey, Lindsey Shelton, Brian Blagg, John Koren, Laura Jenelle Blair
  • Publication number: 20220241309
    Abstract: Disclosed herein are compounds and methods for inhibiting Aha1 for the treatment of tauopathies and neurodegenerative diseases. The Aha1 inhibitor may reduce the interaction between Aha1 and Hsp90. The Aha1 inhibitor may reduce aggregation of tau protein. The Aha1 inhibitor may include a compound selected from KU-177, KU-174, and KU-308.
    Type: Application
    Filed: April 15, 2022
    Publication date: August 4, 2022
    Inventors: Chad Dickey, Lindsey Shelton, Brian Blagg, John Koren, Laura Jenelle Blair
  • Patent number: 11318155
    Abstract: Disclosed herein are compounds and methods for inhibiting Aha1 for the treatment of tauopathies and neurodegenerative diseases. The Aha1 inhibitor may reduce the interaction between Aha1 and Hsp90. The Aha1 inhibitor may reduce aggregation of tau protein. The Aha1 inhibitor may include a compound selected from KU-177, KU-174, and KU-308.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: May 3, 2022
    Assignees: University of South Florida, University of Kansas
    Inventors: Chad Dickey, Lindsey Shelton, Brian Blagg, John Koren, Laura Blair
  • Publication number: 20210128597
    Abstract: Disclosed herein are compounds and methods for inhibiting Aha1 for the treatment of tauopathies and neurodegenerative diseases. The Aha1 inhibitor may reduce the interaction between Aha1 and Hsp90. The Aha1 inhibitor may reduce aggregation of tau protein. The Aha1 inhibitor may include a compound selected from KU-177, KU-174, and KU-308.
    Type: Application
    Filed: February 23, 2018
    Publication date: May 6, 2021
    Inventors: Chad Dickey, Lindsey Shelton, Brian Blagg, John Koren, Laura Blair